MEDIA RELEASE PR38472
CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
CAMBRIDGE, Feb. 25 /PRNewswire-AsiaNet/ --
From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the
development and commercialisation of an important programme focused on cancer.
Under the terms of the new agreement, CellCentric will receive from Takeda Pharmaceutical Company
Limited an upfront payment and pre-clinical and clinical milestones, in addition to royalties. Based on the
royalties and milestones defined, the overall deal could be worth in excess of $200m to CellCentric over the
course of the agreement.
This is a pioneering deal for the emerging area of epigenetics, demonstrating the commercial interest in
novel epigenetic targets beyond HDACs (histone deacetylases) and DNMTs (DNA methyltransferases).
Therapeutic research will be initiated by Takeda's Research Group. Development of molecules stemming from
this agreement will be completed by Millennium: The Takeda Oncology Company, which is responsible for
Takeda's global oncology development strategy.
Many diseases including cancer involve a loss of cell fate control. In many cases this is associated with
aberrant epigenetic changes to chromatin: dynamic modifications of DNA and its associated proteins,
including histones. These epigenetic alterations are caused by a range of enzymes. Initial therapeutic interest
has been focused on inhibiting HDAC and DNMTs. It has become increasingly clear that there are many other
key epigenetic related enzymes that can be targeted and which may offer greater specificity of action. These
include histone methyltransferases, demethylases and ubiquitin-related enzymes.
CellCentric has an innovation platform built upon relationships with over 30 world leading research labs in
epigenetics. The company has identified and prioritised multiple next generation targets and runs a series of
active drug discovery programmes from its centre in Cambridge, UK. As programmes move forward,
CellCentric is able to gain continued benefit and support from multiple Principal Investigators within its
network.
With an extensive portfolio and rich pipeline, CellCentric's strategy is to develop some target programmes
through licences and collaborations with Pharmaceutical companies while retaining other programmes
for development itself.
Dr Hiroyuki Odaka, General Manager of the Pharmaceutical Research Division of Takeda said "Epigenetics
is an important area for novel oncology therapeutics. This new agreement demonstrates our commitment to
researching and pioneering the best ways to treat cancer."
Dr Will West, CEO of CellCentric added "This licence is a strong endorsement of the way we are
approaching innovation in epigenetics. This is an area that is no longer seen as just interesting, but as a
necessity for pharmaceutical companies growing their armoury for tackling intractable diseases such as
cancer".
Notes:
CellCentric is a biotechnology company focused on epigenetics. Formed in 2004, it works with over 30
academic labs worldwide to identify, patent and commercialise product opportunities. CellCentric currently has
7
novel target discovery programmes ongoing, focused on cancer, as well as multiple projects related to
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on
pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to striving toward better health for individuals and progress in
medicine by developing superior pharmaceutical products. Additional information about Takeda is available
SOURCE: CellCentric Ltd
Translations:
NEWS 
